|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, the wound healing response synergises with YAP to drive metaplastic transformation of SCC to spSCC.
|
30231971 |
2018 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further, we find that cells with nuclear YAP and TAZ localize to the invasive front in well-differentiated SCC, whereas nuclear YAP is homogeneously expressed in spindle cell carcinoma undergoing EMT We also show that mouse BCC and SCC are enriched for YAP gene signatures.
|
29875149 |
2018 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comprehensive "-omics" interrogation of PDCs derived from one of these models revealed YAP1 as a putative biomarker for treatment response and survival in ~24% of oral squamous cell carcinoma.
|
28874669 |
2017 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
More importantly, we determine that S100A7 overexpression partially rescues lung ADC to SCC transdifferentiation inhibited by YAP overexpression in all tested cells, suggesting that S100A7 and YAP have the opposite effects on lung ADC to SCC conversion.
|
28177901 |
2017 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These studies suggest that YAP1 and ∆Np63α may be important sulforaphane cancer preventive targets in epidermal squamous cell carcinoma.
|
29088716 |
2017 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
ACTL6A Is Co-Amplified with p63 in Squamous Cell Carcinoma to Drive YAP Activation, Regenerative Proliferation, and Poor Prognosis.
|
28041841 |
2017 |
|
Squamous cell carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Importantly, either the positive correlation between S100A7 and YAP phosphorylation at S127 or the negative correlation between S100A7 and ΔNp63 is also observed in skin SCC tissues.
|
28923839 |
2017 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we uncover that S100A7 induction by the Hippo-YAP pathway displays different characteristic in cervical and glossopharyngeal SCC.
|
27907036 |
2016 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
LATS2 induced by TNF-alpha and inhibited cell proliferation and invasion by phosphorylating YAP in oral squamous cell carcinoma.
|
25782587 |
2015 |
|
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of the present study was to investigate the expression of miR-138 in OSCC tumor tissues and several OSCC cell lines and validated its interaction with the 3'-untranslated region (3'-UTR) of Yes-associated protein 1 (YAP1).
|
26239136 |
2015 |
|
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Supporting this premise, we determined that nuclear YAP and TAZ activity drives OSCC cell proliferation, survival, and migration in vitro, and is required for OSCC tumor growth and metastasis in vivo.
|
25794680 |
2015 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we show that YAP, the major effector of the Hippo pathway, displays a distinct activation pattern in lung adenocarcinoma (ADC) and squamous cell carcinoma (SCC); YAP is initially activated by LKB1 loss in lung ADC, which upregulates ZEB2 expression and represses DNp63 transcription in a default manner.
|
25115923 |
2014 |
|
Squamous cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We also find new genes with recurrent amplifications (for example, DROSHA, YAP1) or homozygous deletions (for example, DDX3X) in OSCC-GB.
|
24292195 |
2013 |
|
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of Yes-associated protein 1 gene and protein in oral squamous cell carcinoma.
|
23422184 |
2013 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We also found an inverse correlation between αE-catenin abundance and Yap1 activation in human squamous cell carcinoma tumors.
|
21610251 |
2011 |